Plenary Session 1
Chair: Jair Soares
Developments in Brain Stimulation for Depression
Jeff Daskalakis, Campbell Family Mental Health Research Institute, Canada

Digital Technology to access and efficiently manage depression and anxiety in
primary care and the general community: results of the PReDicT and REBOOT studies.

Richard Morriss, University Of Nottingham, UK
Michael Browning,
University of Oxford,UK
Henricus Ruhe,
Radboud University Medical Centre, The Netherlands,
Susan Brown, University of Nottingham, UK 

Early Life Stress in Affective Disorders: From Neuroscience to Diagnosis and Treatment.

Mario Juruena,
King's College London, UK
Bruno Etain, University Paris Diderot and Assistance Publique des Hopitaux de Paris, France,
Monica Aas, University of Oslo, Norway,            Rodrigo Machado-Vieira,
University of Texas Medical School, USA

Translating evidence from nutritional epidemiology to interventions for depression: challenges, results and future perspectives.

Brenda Pennix, Yuri Milaneschi,
Amsterdam UMC, The Netherlands, Michael Berk, Deakin University, Australia, Olivia I. Okereke, Massachusetts General Hospital and Harvard Medical School, Boston, USA, Mariska Bot, Amsterdam UMC, The Netherlands

New platforms and approaches to the prediction of treatment outcomes in major depressive disorder.

Rudolf Uher,
Dalhousie University, Canada
Sidney Kennedy, St. Michael's Hospital, Canada,
Oliver Pain, King's College London, Uk,
Anneka Tomlinson, University of Oxford, UK

Psilocybin Therapy for Treatment Resistant Depression: A Good or Bad Trip?

James Rucker,
Kings College London, UK
Robin Carhart-Harris,
Taylor Lyons, Imperial College London,UK,
Aster Daniel, King’s College London, UK

Sleep & Circadian Dysregulation: From Diagnosis to Treatment.

Bruno Etain, Paris Diderot University, France
Ian Hickie, The University of Sydney, Australia, Havard Kallestad, Ntnu, Norway

O-001 A Web-based Decision Aid Tool for Disclosure of a Mental Health Condition in the Workplace: a Randomised Controlled Trial.

Elizabeth Stratton, University of Sydney, Australia

O-006 The role of early life stress in the clinical course and outcome of Bipolar Disorder.

Mario Juruena,
King's College London, UK

O-002 The significance of comorbid alcohol use disorder in psychiatric patients with major depressive disorder.

Mikael Holma, University of Helsinki and Helsinki University Hospital, Finland

O-007 Impact of Early Life Stress on Affective Disorder Treatment Outcomes. [Systematic Review]

Filip Eror, King’s College London, UK

O-003 Effects of aerobic exercise on gut microbiota in adolescents with subthreshold mood syndromes and clinnicall-well adolescents: a 12-week, randomized controlled trial.

Runhua Wang, Guangzhou Medical University, China

O-008 Severity of Suicide Attempt is Related to Epigenetic and Transcriptional Changes in the CYP2D6 Gene.

Jussi Jokinen, Psychiatry Umea University, Sweden

O-004 Are sleep disturbance and fatigue present in various mental and substance use disorders?

Sonia Mccallum, The Australian National University, Australia

O-009 Suicide, Opioid Overdose, and the Gray Areas in Between.

Richard K Ries, University of Washington, USA

O-005 Positive mental health as a predictor of recovery from mental illness.

Matthew Iasiello, Flinders University, Australia

O-010 Comparison of Treatment Outcomes, Sociodemographic and Clinical Characteristics of Black and Minority Ethnic Service Users in a Southwark IAPT Service.

Rebecca Tucker, King's College London, UK

O-011 Reduced gray matter volume in the subgenual anterior cingulate underlies negative psychobehavioral outcomes in early-maturing girls.

Naohiro Okada, International Research Center for Neurointelligence (WPI-IRCN), The University of Tokyo, Japan

The bipolar brain: from risk to treatment, from treatment to aging.

Allan Young, Nefize Yalin, King's College London, UK,
David Cousins, Newcastle University, UK
Tomas Hajek, Dalhouise University, Canada

Computational Neuroscience Approaches in Mood Disorders.

Henricus Ruhe,
Radboud University Medical Center, The Netherlands,
Douglas Steele,
University Of Dundee, UK, Sophie Brolsma, Radboud University, The Netherlands,
Gregor Hasler,
Universitat Bern, Switzerland

New approaches to understanding the trajectories of mood disorders across the life course.

Karine Macritchie, South London and Maudsley Hospital, UK
Ian Hickie, The University of Sydney, Australia, Bruno Etain,
Diderot University, France

O-012 A double-blind dose-response study of casein glycomacropeptide (Lacprodan CGMP-20). Possible new treatments for mania.

Erik Roj Larsen, University Clinic, Mental Health Service, Denmark

O-017 Help seeking attitudes and intentions for anxiety in adolescents: The role of anxiety literacy and stigma.

Alison Calear, The Australian National University, Australia

O-022 Extensive blood-brain barrier leakage is a biomarker of neuroprogression in bipolar disorder.

Cynthia Calkin, Dalhousie University, Canada

O-013 Mineralocorticoid Receptor Agonist as a Predictor of Treatment Outcome in Treatment Resistant Depression with Early Life Stress.

Mario Juruena, King’s College London, UK

O-018 The association of antihypertensive use and depressive symptoms in a large older population with uncomplicated hypertension living in Australia and the United States: A cross-sectional study.

Bruno Agustini, Deakin University, Australia

O-023 Electrodermal hyporeactivity as biopsychological marker for suicidal vulnerability in depression indicating Hippocampal Disorienting.

Lars H Thorell, Linkoping University, Sweden

O-014 The Neuroactive Steroid and GABAA Receptor Positive Allosteric Modulators Brexanolone Injection and SAGE-217 in the Treatment of Mood Disorders: Results from Recent Placebo-controlled Studies.

Brian Werneburg, Sage Therapeutics,USA

O-019 Cognitive Remediation Therapy confers broad benefits to euthymic patients with bipolar disorder.

Rebecca Strawbridge, King's College London, UK

O-024 Altered spatiotemporal dynamics of stimulus-evoked neural responses in clinical depression: a Magnetoencephalography (MEG) study in Saudi Arabia.

Fahad Aldosary, Alamal Mental Health Complex, Saudi Arabia

O-015 Bidirectional longitudinal association of omega-3 polyunsaturated fatty acids with depressive disorders.

Carisha S. Thesing, Amsterdam University Medical Center, The Netherlands

O-020 Enhancing the clinical effectiveness of depression screening using patient-targeted feedback in general practices: The GET.FEEDBACK.GP multicentre randomized controlled trial.

Sebastian Kohlmann, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

O-025 Food craving in bipolar disorder.

Martina Platzer, Medical University Graz, Austria

O-016 Th17 and B cells as predictors of responsiveness to add-on cyclooxygenase-2 (COX-2) therapy in major depressive disorder.

Gara Arteaga Henriquez, Vall d'Hebron Research Institute (VHIR), Spain

O-021 Symptoms overlap in ADHD and Bipolar Disorder in paediatric population: An overlooked issue?

Krzysztof Maria Wilczyński, Medical University of Silesia, Poland

O-026 Metabolic parameters as predictors of bipolarity in first-episode psychosis: a retrospective cohort study.

Pedro Oliveira,University of Coimbra, Portugal

17:00 - 18:00

Actigraphy research in affective disorders: a global overview from the mMARCH consortium.

Femke Lamers,
Amsterdam UMC, The Netherlands,
Joanne S. Carpenter,
University of Sydney, Australia;
Jennifer Glaus,
Lausanne University Hospital, Switzerland
Jihui Zhang,
The Chinese University of Hong Kong, China
Sonia Difrancesco,
Amsterdam UMC, Netherlands
Kathleen R Merikangas,
National Institute of Mental Health, USA

Pharmacogenetics in unipolar and bipolar depression: review of the latest clinical evidence and new research directions.

Simon Kung,
Mayo Clinic, USA
Alfredo B. Cuéllar Barboza, Universidad Autonoma de Nuevo Leon, Mexico,
Mark Frye,
Mayo Clinic, USA,
Chiara Fabbri,
King’s College London, UK

Suicidality in Pediatric Mood Disorders: Implications for Clinical Practice.

Iram Kazimi,
University Of Texas Health Sciences Center, USA, Ana Ugueto, Cristian Patrick Zeni, McGovern Medical School at the University of Texas Health Science Center, USA,